Apixaban

also known as Eliquis · Apixaban (Eliquis) · Apixaban IR · Apixaban MR1 · Apixaban MR2 · Apixaban MR3 · Apixiban · Eliquis 2,5mg · +1 more

Small molecule

Developed for: venous thromboembolism · atrial fibrillation · thrombotic disease · pulmonary embolism · ischemic stroke · cirrhosis of liver · stroke disorder · end stage renal failure
+45 more
· intracerebral hemorrhage · portal vein thrombosis · portal hypertension · acute coronary syndrome · aortic valve stenosis · cancer · nephrotic syndrome · plasma cell myeloma · acquired polycythemia vera · acute myocardial infarction · atrial flutter · blood coagulation disease · cerebral sinovenous thrombosis · COVID-19 · essential thrombocythemia · patent foramen ovale · primary myelofibrosis · spinal cord injury · transient ischemic attack · acute lymphoblastic leukemia · antiphospholipid syndrome · aortic valve disorder · autoimmune hemolytic anemia · cerebral infarction · cerebrovascular disorder · heparin-induced thrombocytopenia · impaired renal function disease · ischemic disease · limb ischemia · myocardial infarction · neoplasm · pregnancy disorder · thrombocytopenia · vascular malformation · vascular occlusion disorder · diabetes mellitus · hyperheparinemia · infective endocarditis · osteoarthritis, knee · portal hypertension, noncirrhotic · sickle cell disease · staphylococcal toxemia · staphylococcus aureus infection · Tako-tsubo cardiomyopathy · traumatic brain injury
Investigated by: Bristol-Myers Squibb · Pfizer · Population Health Research Institute · Assistance Publique - Hôpitaux de Paris · Northern Jiangsu People's Hospital · Yonsei University
+206 more
· McMaster University · Medtronic · Ministry of Health, France · Oslo University Hospital · Second Affiliated Hospital, School of Medicine, Zhejiang University · Aalborg University Hospital · Aarhus University Hospital · Academic and Community Cancer Research United · Centre Hospitalier Universitaire Vaudois · Columbia University · Gødstrup Hospital · Hamilton Health Sciences Corporation · Helsinki University Central Hospital · Imperial College London · Insel Gruppe AG, University Hospital Bern · National Cancer Institute (NCI) · National Heart, Lung, and Blood Institute (NHLBI) · Odense University Hospital · Ottawa Hospital Research Institute · Rigshospitalet, Denmark · TAHO Pharmaceuticals Ltd. · Universitaire Ziekenhuizen KU Leuven · University College, London · University Hospital of Saint-Etienne · University Hospital, Brest · University Hospital, Caen · University of Aarhus · University of Birmingham · University of Edinburgh · University of North Carolina, Chapel Hill · Aalborg University · Abbott · Abbott Medical Devices · Action Research Group · Albany Medical College · Alfried Krupp Krankenhaus · American College of Clinical Pharmacy · Apsen Farmaceutica S.A. · Arianna Anticoagulazione Foundation · Artivion Inc. · Asan Medical Center · Asian Institute Of Medical Sciences · Aston University · Atrial Fibrillation Network · Azienda Ospedaliera di Perugia · Baxter Healthcare Corporation · Bayer · Beckwith Foundation · Biofarma · Boehringer Ingelheim · Brigham and Women's Hospital · Bristol-Meyers Squibb & Pfizer · Canadian Hematology Society · Canadian Institutes of Health Research (CIHR) · Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network · Celgene Corporation · Centre Hospitalier St Anne · Centre Hospitalier Universitaire Dijon · Charles University, Czech Republic · Chief Scientist Office of the Scottish Government · Christopher Granger, MD · Clinical Practice Research Datalink · Clinical Urology and Epidemiology Working Group · Combined military hospital lahore · DR. XAVIER FREIXA · Dartmouth-Hitchcock Medical Center · Dermadia · Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) · Dt&Sanomedics · Duke Clinical Research Institute · Dutch Heart Foundation · Ewha Womans University Seoul Hospital · Fadoi Foundation, Italy · French National Institute of Health and Medical Research · all 212 on the full record

Regulatory milestones approvals, filings & regulatory actions · 5 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (3)	US (FDA)	ELIQUIS	—	2014-03-13 – 2025-04-17	fda.gov ↗
Approved	US (FDA)	ELIQUIS	—	2012-12-28	fda.gov ↗
Approved	EU (EMA)	Eliquis	—	2011-05-18	europa.eu ↗

Trials 170 · started per year

today

EU approved 2011

US approved 2012

200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 05 trials
Phase 0	NCT07011095	Sep 2025 → Feb 2027 expected	atrial fibrillation	Population Health Research Institute	Not yet recruiting	No outcome recorded
Phase 0	NCT06933056	Sep 2025 → Sep 2026 expected	—	University of Michigan	Recruiting	No outcome recorded
Phase 0	NCT06886516	Feb 2025 → Jul 2027 expected	pulmonary embolism, thrombocytopenia, venous thromboembolism	Rushad Patell	Recruiting	No outcome recorded
Phase 0	NCT05995119	Dec 2022	—	TAHO Pharmaceuticals Ltd.	Completed	No outcome recorded
Phase 0	NCT03935451	Sep 2021 → Dec 2025	Crohn disease, pulmonary embolism, ulcerative colitis, venous thromboembolism	McMaster University	Unknown	No outcome recorded
Phase 124 trials
Phase 1	NCT07265466	Nov 2025 → Mar 2026 overdue	—	Onconic Therapeutics Inc.	Recruiting	No outcome recorded
Phase 1	NCT06372483	Feb → Aug 2024 overdue	blood coagulation disease	VarmX B.V.	Active not recruiting	No outcome recorded
Phase 1	NCT05723510	Mar → Jul 2023	—	HK inno.N Corporation	Completed	No outcome recorded
Phase 1	NCT04874428	May 2021 → Jun 2026 overdue	cirrhosis of liver	Insel Gruppe AG, University Hospital Bern	Recruiting	No outcome recorded
Phase 1	NCT04278729	Apr 2021 → Sep 2023	membranous glomerulonephritis, nephrotic syndrome	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 1	NCT04809818	Mar → Aug 2021	ischemic stroke	Lumosa Therapeutics Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT04191928	Mar → Jul 2020	malignant pancreatic neoplasm, pulmonary embolism, venous thromboembolism	Thomas Jefferson University	Completed	No outcome recorded
Phase 1	NCT04006093	Dec 2019 → Dec 2022	chronic renal failure syndrome	University Hospital, Caen	Completed	No outcome recorded
Phase 1	NCT03509883	Apr → Jun 2018	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT02599532	Apr 2017 → Jun 2019	nephrotic syndrome, proteinuria	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 1	NCT02912234	Sep → Oct 2016	venous thromboembolism	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT02080858	May → Oct 2014	acute coronary syndrome, atrial fibrillation	Medical University of Vienna	Completed	No outcome recorded
Phase 1	NCT02101112	Mar → May 2014	thrombotic disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT02074358	Feb → Apr 2014	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT01707394	Jan 2013 → Jun 2020	thrombotic disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT02034591	Oct → Nov 2011	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT01437839	Sep → Oct 2011	—	Pfizer	Completed	No outcome recorded
Phase 1	NCT01195727	Jul 2011 → Jun 2012	venous thromboembolism	Bristol-Myers Squibb	Terminated	No outcome recorded
Phase 1	NCT02034578	Jul → Aug 2011	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT01340586	Jun → Sep 2011	end stage renal failure	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT02034565	Feb → Mar 2010	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT00914641	Jun → Aug 2009	thrombotic disease	Pfizer	Completed	No outcome recorded
Phase 1	NCT02262533	Jun 2007	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT02262520	Jan → Mar 2006	—	Bristol-Myers Squibb	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT04850378	Mar 2021 → May 2024	nephrotic syndrome, thrombotic disease	University of Aarhus	Completed	No outcome recorded
Phase 1/2	NCT04504318	Aug 2020 → Jun 2024	venous thromboembolism	Stanford University	Completed	No outcome recorded
Phase 231 trials
Phase 2	NCT07246005	Dec 2026 → Dec 2027 expected	thrombotic disease	Queen Mary University of London	Not yet recruiting	No outcome recorded
Phase 2	NCT06729034	Feb 2025 → Dec 2030 expected	vascular malformation	Oslo University Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT06689436	Nov 2024 → Jan 2025	—	TAHO Pharmaceuticals Ltd.	Completed	No outcome recorded
Phase 2	NCT05869591	Jan 2024 → Jun 2026 overdue	cirrhosis of liver	Centre Hospitalier Universitaire Vaudois	Recruiting	No outcome recorded
Phase 2	NCT05618808	May 2023 → May 2024	venous thromboembolism	Regeneron Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT05683808	Jan 2023 → Dec 2026 expected	astrocytoma (excluding glioblastoma), glioblastoma, venous thromboembolism	University of Vermont Medical Center	Recruiting	No outcome recorded
Phase 2	NCT05006287	Oct 2022 → May 2024	atrial fibrillation	St. Paul's Hospital, Canada	Unknown	No outcome recorded
Phase 2	NCT05088928	Mar → May 2022	COVID-19	Scotmann Pharmaceuticals	Unknown	No outcome recorded
Phase 2	NCT05089227	Feb 2022 → Aug 2028 expected	autoimmune hemolytic anemia, venous thromboembolism	Centre Hospitalier Universitaire Dijon	Recruiting	No outcome recorded
Phase 2	NCT04865978	Dec 2021 → Oct 2023	heart failure	Palak Shah	Completed	No outcome recorded
Phase 2	NCT04952792	May 2021 → Dec 2022	atrial fibrillation	Hospital Universitari de Bellvitge	Completed	No outcome recorded
Phase 2	NCT04696120	Mar 2021 → Aug 2022	cardiac rhythm disease, cerebrovascular disorder, heart failure	Korea University Guro Hospital	Unknown	No outcome recorded
Phase 2	NCT04243122	Feb 2021 → Oct 2023	acquired polycythemia vera, essential thrombocythemia, primary myelofibrosis, venous thromboembolism	Ottawa Hospital Research Institute	Completed	No outcome recorded
Phase 2	NCT04106700	Apr 2019 → Aug 2020	venous thromboembolism	La Fe Health Research Institute	Terminated	No outcome recorded
Phase 2	NCT03594045	Dec 2018 → Oct 2019	heparin-induced thrombocytopenia	Massachusetts General Hospital	Terminated	No outcome recorded
Phase 2	NCT03251482	Nov 2017 → Nov 2018	—	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 2	NCT03200613	Sep 2017 → Jul 2019	spinal cord injury, venous thromboembolism	McMaster University	Terminated	No outcome recorded
Phase 2	NCT03310021	Aug 2017 → Aug 2019	hemorrhagic disease	Portola Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT03139487	Aug 2017 → Sep 2021	ampulla of vater cancer, esophageal cancer, gastric cancer, gastroesophageal cancer +3	Asan Medical Center	Unknown	No outcome recorded
Phase 2	NCT04041843	Jun 2017 → May 2021	venous thromboembolism	New York Medical College	Completed	No outcome recorded
Phase 2	NCT02998905	Apr 2017 → Oct 2019	atrial fibrillation, intracerebral hemorrhage	Population Health Research Institute	Completed	No outcome recorded
Phase 2	NCT02981472	Jan 2017 → Oct 2021	thrombotic disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 2	NCT03456648	Sep 2016 → Aug 2018	end stage renal failure, poisoning	Universitaire Ziekenhuizen KU Leuven	Completed	No outcome recorded
Phase 2	NCT02749617	Aug 2016 → Jan 2018	—	University of British Columbia	Terminated	No outcome recorded
Phase 2	NCT02809469	Aug 2016 → Aug 2018	atrial fibrillation	Hamilton Health Sciences Corporation	Unknown	No outcome recorded
Phase 2	NCT02366871	Apr 2015 → Jun 2019	female reproductive organ cancer, venous thromboembolism	University of Colorado, Denver	Completed	No outcome recorded
Phase 2	NCT02565693	Sep 2014 → Jan 2021	atrial fibrillation, intracerebral hemorrhage	UMC Utrecht	Completed	No outcome recorded
Phase 2	NCT00852397	Apr 2009 → Dec 2010	acute coronary syndrome	Pfizer	Terminated	No outcome recorded
Phase 2	NCT00787150	Jun 2008 → Sep 2009	atrial fibrillation	Pfizer	Completed	No outcome recorded
Phase 2	NCT00313300	May 2006 → May 2008	acute coronary syndrome	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 2	NCT00252005	Nov 2005 → Feb 2007	venous thromboembolism	Bristol-Myers Squibb	Completed	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT01924325	Jan 2014 → Dec 2015	transient ischemic attack	Xijing Hospital	Unknown	No outcome recorded
Phase 2/3	NCT00097357	Oct 2004 → Dec 2005	pulmonary embolism, venous thromboembolism	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 345 trials
Phase 3	NCT07709780	Jun 2026 → Jul 2028 expected	thrombotic disease	University of Arizona	Recruiting	No outcome recorded
Phase 3	NCT07471139	Jun 2026 → Jun 2029 expected	heart failure, hemorrhagic disease, stroke disorder, thrombotic disease	Columbia University	Not yet recruiting	No outcome recorded
Phase 3	NCT07160686	Mar 2026 → Sep 2029 expected	venous thromboembolism	University of Birmingham	Not yet recruiting	No outcome recorded
Phase 3	NCT07005024	Oct 2025 → Aug 2035 expected	cancer, venous thromboembolism	University of Vermont	Recruiting	No outcome recorded
Phase 3	NCT05687448	Sep 2025 overdue	aortic valve disorder	Assistance Publique - Hôpitaux de Paris	Not yet recruiting	No outcome recorded
Phase 3	NCT06742567	Dec 2024 → Nov 2025 overdue	acute myocardial infarction, thrombotic disease	National Institute of Cardiovascular Diseases, Pakistan	Recruiting	No outcome recorded
Phase 3	NCT06045858	Oct 2024 → Oct 2027 expected	atrial fibrillation	University Hospital, Caen	Not yet recruiting	No outcome recorded
Phase 3	NCT05387954	Jul 2023 → Jul 2031 expected	ischemic stroke, patent foramen ovale	Assistance Publique - Hôpitaux de Paris	Recruiting	No outcome recorded
Phase 3	NCT05825573	May 2023 → Feb 2025 overdue	ST-elevation myocardial infarction, heart failure, thrombotic disease	Nîmes University Hospital	Active not recruiting	No outcome recorded
Phase 3	NCT04981327	Sep 2022 → Aug 2026 overdue	venous thromboembolism	University Hospital, Geneva	Not yet recruiting	No outcome recorded
Phase 3	NCT05198960	Jul 2022 → Jul 2027 expected	acquired polycythemia vera, essential thrombocythemia, primary myelofibrosis	University Hospital, Brest	Recruiting	No outcome recorded
Phase 3	NCT05035277	Dec 2021 → Jun 2026	aortic valve stenosis	Oslo University Hospital	Completed	No outcome recorded
Phase 3	NCT04788355	Jul → Nov 2020	pregnancy disorder	Universidade do Vale do Sapucai	Completed	No outcome recorded
Phase 3	NCT04142658	May 2020 → Dec 2022	aortic valve stenosis	Artivion Inc.	Terminated	No outcome recorded
Phase 3	NCT04229264	Jan 2020 → Feb 2022	limb ischemia	Science Valley Research Institute	Unknown	No outcome recorded
Phase 3	NCT04045665	Dec 2019 → Aug 2026 overdue	atrial fibrillation, hemorrhagic disease, stroke disorder	Icahn School of Medicine at Mount Sinai	Recruiting	No outcome recorded
Phase 3	NCT03961334	Dec 2019 → Jan 2025	ischemic stroke	University of Zurich	Unknown	No outcome recorded
Phase 3	NCT03996772	Jun 2019 → May 2024	atrial fibrillation, intracerebral hemorrhage	Imperial College London	Completed	No outcome recorded
Phase 3	NCT03243175	Jan 2019 → Jan 2029 expected	atrial fibrillation, intracerebral hemorrhage	University Hospital, Lille	Recruiting	No outcome recorded
Phase 3	NCT03153150	Mar 2018 → Mar 2021	atrial fibrillation, atrial flutter, intracerebral hemorrhage, subarachnoid hemorrhage	University of Edinburgh	Completed	No outcome recorded
Phase 3	NCT05208398	Feb 2018 → Sep 2021	thrombotic disease	Saud Al Babtain Cardiac Center	Completed	No outcome recorded
Phase 3	NCT03192215	Jan 2018 → Mar 2023	stroke disorder	Columbia University	Terminated	No outcome recorded
Phase 3	NCT03285438	Nov 2017 → Nov 2023	venous thromboembolism	University Hospital, Brest	Completed	No outcome recorded
Phase 3	NCT03080883	Jul 2017 → Jun 2022	cerebral sinovenous thrombosis, hematopoietic and lymphoid cell neoplasm, metastatic malignant neoplasm, pulmonary embolism +1	Academic and Community Cancer Research United	Completed	No outcome recorded
Phase 3	NCT03181386	May 2017 → Nov 2020	atrial fibrillation, hemorrhagic disease, periodontal disorder	University of Sao Paulo General Hospital	Completed	No outcome recorded
Phase 3	NCT03045406	Apr 2017 → Jun 2019	venous thromboembolism	Fadoi Foundation, Italy	Completed	No outcome recorded
Phase 3	NCT02982590	Nov 2016 → Nov 2018	thrombotic disease	Universiti Sains Malaysia	Completed	No outcome recorded
Phase 3	NCT02664155	Oct 2016 → Nov 2021	impaired renal function disease	University Hospital of Saint-Etienne	Terminated	No outcome recorded
Phase 3	NCT02664649	Aug 2016 → Oct 2020	aortic valve stenosis	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT02427126	Dec 2015 → Aug 2020	—	University Hospital Tuebingen	Completed	No outcome recorded
Phase 3	NCT02585713	Nov 2015 → Apr 2018	cerebral sinovenous thrombosis, hepatic vein thrombosis, isolated mesenteric vein thrombosis, isolated splenic vein thrombosis +4	Academic and Community Cancer Research United	Completed	No outcome recorded
Phase 3	NCT02369653	Oct 2015 → Jul 2021	acute lymphoblastic leukemia	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT02283294	Apr 2015 → Jun 2019	atrial fibrillation, transient ischemic attack	University of South Florida	Completed	No outcome recorded
Phase 3	NCT02066454	Jun 2014 → Jul 2016	plasma cell myeloma, venous thromboembolism	University Hospital, Grenoble	Completed	No outcome recorded
Phase 3	NCT01780987	Jan 2013 → Sep 2014	pulmonary embolism, venous thromboembolism	Pfizer	Completed	No outcome recorded
Phase 3	NCT01675076	Jan 2013 → Oct 2017	—	Ottawa Heart Institute Research Corporation	Completed	No outcome recorded
Phase 3	NCT00643201	Jul 2008 → Mar 2013	venous thromboembolism	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00633893	May 2008 → Aug 2012	venous thromboembolism	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00562289	Dec 2007 → Dec 2016	atrial septal aneurysm, ischemic stroke, migraine disorder, patent foramen ovale	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT00496769	Aug 2007 → Nov 2010	atrial fibrillation	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00457002	Jun 2007 → May 2011	pulmonary embolism, venous thromboembolism	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00452530	Jun 2007 → Jan 2009	pulmonary embolism, venous thromboembolism	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00423319	Mar 2007 → Sep 2009	pulmonary embolism, venous thromboembolism	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00412984	Dec 2006 → May 2011	atrial fibrillation, atrial flutter	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00371683	Nov 2006 → May 2008	pulmonary embolism, venous thromboembolism	Bristol-Myers Squibb	Completed	No outcome recorded

Phase 444 trials
Phase 4	NCT07713875	Aug 2026 → Nov 2027 expected	metastatic malignant neoplasm in the spinal cord, pulmonary embolism, venous thromboembolism	James Bayley	Not yet recruiting	No outcome recorded
Phase 4	NCT07609654	Jun 2026 → Jun 2029 expected	atrial fibrillation, intracerebral hemorrhage, ischemic stroke	Second Affiliated Hospital, School of Medicine, Zhejiang University	Not yet recruiting	No outcome recorded
Phase 4	NCT07521332	Apr 2026 → Apr 2027 expected	cirrhosis of liver, esophageal varices, hepatic encephalopathy, portal hypertension +1	Asian Institute Of Medical Sciences	Recruiting	No outcome recorded
Phase 4	NCT07404345	Mar 2026 → Mar 2028 expected	end stage renal failure	Hospital Civil de Guadalajara	Not yet recruiting	No outcome recorded
Phase 4	NCT07237308	Dec 2025 → Jul 2029 expected	atrial fibrillation, intracranial arteriosclerosis, ischemic disease, stroke disorder	Yonsei University	Not yet recruiting	No outcome recorded
Phase 4	NCT07189897	Oct 2025 → Sep 2027 expected	head and neck cancer, venous thromboembolism	Kiranya Arnold	Recruiting	No outcome recorded
Phase 4	NCT06486792	Jun 2025 → Dec 2028 expected	atrial fibrillation, cerebral infarction	Assistance Publique - Hôpitaux de Paris	Recruiting	No outcome recorded
Phase 4	NCT06515730	Apr 2025 → Apr 2028 expected	acute myocardial infarction, thrombotic disease	Karolinska Institutet	Recruiting	No outcome recorded
Phase 4	NCT06603870	Dec 2024 → Oct 2029 expected	cancer, prosthesis-related infectious disease, venous thromboembolism	Ottawa Hospital Research Institute	Recruiting	No outcome recorded
Phase 4	NCT06523959	Jun 2024 → Sep 2028 expected	hemorrhagic disease, venous thromboembolism	Clinical Urology and Epidemiology Working Group	Recruiting	No outcome recorded
Phase 4	NCT06401616	May 2024 → Mar 2028 expected	atrial fibrillation	Odense University Hospital	Recruiting	No outcome recorded
Phase 4	NCT05735639	Jan 2024 → Jun 2027 expected	varicose disease, venous thromboembolism	Imperial College London	Recruiting	No outcome recorded
Phase 4	NCT07132515	Aug 2023 → Aug 2025 overdue	cirrhosis of liver, hepatocellular carcinoma, portal vein thrombosis	Mansoura University	Recruiting	No outcome recorded
Phase 4	NCT05973188	May 2023 → Jun 2024	thrombotic disease	Peshawar Institute of Cardiology	Unknown	No outcome recorded
Phase 4	NCT05292846	Jan 2022 → Feb 2024	coronary artery disorder, hemorrhagic disease	Hospital Universitario La Fe	Unknown	No outcome recorded
Phase 4	NCT04700826	Jun 2021 → Dec 2027 expected	atrial fibrillation	University of Birmingham	Recruiting	No outcome recorded
Phase 4	NCT04168203	Mar 2021 → Nov 2023	pulmonary embolism, venous thromboembolism	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 4	NCT04479579	Feb → Oct 2021	cancer, venous thromboembolism	McMaster University	Completed	No outcome recorded
Phase 4	NCT04344717	Dec 2020 → Dec 2024	short bowel syndrome	Universitaire Ziekenhuizen KU Leuven	Unknown	No outcome recorded
Phase 4	NCT04645550	Nov 2020 → Dec 2023	cirrhosis of liver, portal hypertension, splenic disorder, venous thromboembolism	Northern Jiangsu People's Hospital	Completed	No outcome recorded
Phase 4	NCT04512079	Sep 2020 → Dec 2022	COVID-19	Valentin Fuster	Completed	No outcome recorded
Phase 4	NCT04437654	Jul 2020 → Aug 2025	—	Yonsei University	Completed	No outcome recorded
Phase 4	NCT04432220	Jul 2020 → Jul 2026 overdue	—	Yonsei University	Recruiting	No outcome recorded
Phase 4	NCT04489849	Mar 2020 → Mar 2022	—	National Taiwan University Hospital Hsin-Chu Branch	Unknown	No outcome recorded
Phase 4	NCT04128254	Jan → Dec 2020	venous thromboembolism	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Phase 4	NCT04023760	Jun 2019 → Mar 2020	—	University of Saskatchewan	Completed	No outcome recorded
Phase 4	NCT03968393	Jun 2019 → Dec 2028 expected	atrial fibrillation, stroke disorder	Population Health Research Institute	Recruiting	No outcome recorded
Phase 4	NCT05632445	May → Jun 2019	—	DR. XAVIER FREIXA	Completed	No outcome recorded
Phase 4	NCT03678506	Aug 2018 → Sep 2021	venous thromboembolism	Arianna Anticoagulazione Foundation	Terminated	No outcome recorded
Phase 4	NCT07699796	Mar 2018 → Nov 2020	chronic venous insufficiency, varicose disease, venous thromboembolism	Heart, Artery, and Vein Center of Fresno	Completed	No outcome recorded
Phase 4	NCT02958969	Feb 2018 → Jun 2019	plasma cell myeloma, venous thromboembolism	Gregory Piazza	Completed	No outcome recorded
Phase 4	NCT02945280	Feb 2017 → Nov 2021	thrombotic disease, venous thromboembolism	Intermountain Health Care, Inc.	Terminated	No outcome recorded
Phase 4	NCT02942407	Dec 2016 → Jul 2019	atrial fibrillation, end stage renal failure	Christopher Granger, MD	Completed	No outcome recorded
Phase 4	NCT02672709	Apr → Aug 2016	end stage renal failure	Jewish General Hospital	Completed	No outcome recorded
Phase 4	NCT02581176	Apr 2016 → May 2018	neoplasm, venous thromboembolism	University Hospital, Akershus	Completed	No outcome recorded
Phase 4	NCT02464969	Nov 2015 → Apr 2024	venous thromboembolism	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 4	NCT02426944	Oct 2015 → Jul 2019	atrial fibrillation	Charles University, Czech Republic	Completed	No outcome recorded
Phase 4	NCT01938248	May 2015 → Oct 2023	atrial fibrillation, stroke disorder	Population Health Research Institute	Completed	No outcome recorded
Phase 4	NCT01884337	Mar 2015 → Jun 2018	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 4	NCT02295475	Dec 2014 → Apr 2020	antiphospholipid syndrome, thrombotic disease	Scott C. Woller, MD	Completed	No outcome recorded
Phase 4	NCT02227550	Dec 2014 → Apr 2017	atrial fibrillation	Atrial Fibrillation Network	Completed	No outcome recorded
Phase 4	NCT02100228	Jul 2014 → Feb 2017	atrial fibrillation	Pfizer	Completed	No outcome recorded
Phase 4	NCT01884350	Oct 2013 → Jan 2016	atrial fibrillation	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 4	NCT01706146	Oct 2012 → Feb 2015	atrial fibrillation	Northwestern University	Completed	No outcome recorded

Phase not applicable17 trials
—	NCT07461545	Apr 2026 → Sep 2027 expected	cirrhosis of liver, portal hypertension, portal vein thrombosis	Northern Jiangsu People's Hospital	Recruiting	No outcome recorded
—	NCT07461532	Apr 2026 → Sep 2027 expected	cirrhosis of liver, portal hypertension, portal vein thrombosis	Northern Jiangsu People's Hospital	Recruiting	No outcome recorded
—	NCT07559942	Jan → Jun 2026 overdue	end stage renal failure, vascular occlusion disorder	Combined military hospital lahore	Recruiting	No outcome recorded
—	NCT06474182	Sep 2025 → Mar 2027 expected	plasma cell myeloma	University Hospital of Saint-Etienne	Recruiting	No outcome recorded
—	NCT06864052	Mar 2025 → Sep 2029 expected	atrial fibrillation, ischemic stroke	Ewha Womans University Seoul Hospital	Not yet recruiting	No outcome recorded
—	NCT07270263	Nov 2024 → Apr 2026 overdue	leukemia, lymphoma, pulmonary embolism, venous thromboembolism	Medical University of Gdansk	Recruiting	No outcome recorded
—	NCT06057467	Sep 2023 → Oct 2025	atrial fibrillation, ischemic stroke	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
—	NCT05484557	Sep 2023 → Aug 2025 overdue	spinal cord injury	Loewenstein Hospital	Recruiting	No outcome recorded
—	NCT05419583	Nov 2022 → Jun 2024	myocardial infarction	University of Edinburgh	Completed	No outcome recorded
—	NCT05304455	Apr 2022 → May 2023	cirrhosis of liver, portal hypertension, portal vein thrombosis	Northern Jiangsu People's Hospital	Completed	No outcome recorded
—	NCT04974684	Apr 2022 → Mar 2024	thrombotic disease	Institute for Clinical and Experimental Medicine	Completed	No outcome recorded
—	NCT05801068	Aug 2020 → May 2024 overdue	atrial fibrillation, hemorrhagic disease	Seoul National University Hospital	Active not recruiting	No outcome recorded
—	NCT03759938	Jun 2019 → May 2024	atrial fibrillation, ischemic stroke	University College, London	Unknown	No outcome recorded
—	NCT03642509	Jan 2019 → Jan 2026 overdue	atrial fibrillation, stroke disorder	University of Aarhus	Recruiting	No outcome recorded
—	NCT03148457	Nov 2017 → Dec 2022	ischemic stroke	Insel Gruppe AG, University Hospital Bern	Completed	No outcome recorded
—	NCT03136510	Sep 2016 → Dec 2018	atrial fibrillation, blood coagulation disease	Hopital Lariboisière	Terminated	No outcome recorded
—	NCT02504177	Jun 2015 → Jun 2019	atrial fibrillation	Yonsei University	Unknown	No outcome recorded

Also used as a comparator or background therapy in 93 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT06615596 Comparator	Aug 2025 → Jan 2029 expected	atrial fibrillation	China National Center for Cardiovascular Diseases	Recruiting	No outcome recorded
Phase 17 trials
Phase 1	NCT07312851 Background	Jan → Jun 2026	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT05491460 Comparator	Jul 2022 → Dec 2023	—	Doasense GmbH	Unknown	No outcome recorded
Phase 1	NCT05152420 Background	Oct 2021 → Feb 2023	blood coagulation disease	VarmX B.V.	Completed	No outcome recorded
Phase 1	NCT03083782 Comparator	Apr → Jun 2017	venous thromboembolism	Thomas Jefferson University	Completed	No outcome recorded
Phase 1	NCT03083704 Background	Feb → Sep 2017	hemorrhagic disease	Portola Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT02946944 Comparator	Oct 2016 → Oct 2020	pulmonary embolism	Meshalkin Research Institute of Pathology of Circulation	Unknown	No outcome recorded
Phase 1	NCT02270918 Comparator	Nov → Dec 2014	thrombotic disease	Thomas Jefferson University	Completed	No outcome recorded

Phase 212 trials
Phase 2	NCT07175428 Comparator	Oct 2025 → Feb 2027 expected	atrial fibrillation	Regeneron Pharmaceuticals	Recruiting	No outcome recorded
Phase 2	NCT04002011 Comparator	Mar 2022 → Jan 2023	bleeding disorder, vascular-type	Laval University	Withdrawn	No outcome recorded
Phase 2	NCT04218266 Comparator	Jan 2020 → Oct 2021	atrial fibrillation	Bayer	Completed	No outcome recorded
Phase 2	NCT03987711 Comparator	Dec 2019 → Dec 2022	atrial fibrillation, end stage renal failure	Unity Health Toronto	Completed	No outcome recorded
Phase 2	NCT03398434 Comparator	Oct 2018 → Nov 2019	atrial fibrillation	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 2	NCT03276143 Comparator	Sep 2017 → Aug 2018	osteoarthritis, knee	Bayer	Completed	No outcome recorded
Phase 2	NCT03288454 Background	Aug 2017 → Aug 2019	—	AMAG Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT02450682 Comparator	Feb 2016 → Jan 2017	atrial fibrillation	Mayo Clinic	Withdrawn	No outcome recorded
Phase 2	NCT02378623 Comparator	May 2015 → Jan 2020	patent foramen ovale	Mayo Clinic	Withdrawn	No outcome recorded
Phase 2	NCT02048865 Comparator	Mar 2014 → Oct 2018	cancer, venous thromboembolism	Ottawa Hospital Research Institute	Completed	No outcome recorded
Phase 2	NCT01758432 Background	Dec 2012 → Sep 2015	—	Portola Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00320255 Comparator	Jun 2006 → Jan 2009	cancer, pulmonary embolism, thrombotic disease	Bristol-Myers Squibb	Completed	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT02889562 Comparator	Sep 2016 → May 2019	atrial fibrillation, stroke disorder, venous thromboembolism	Sanford Health	Completed	No outcome recorded
Phase 2/3	NCT02829957 Comparator	Sep 2016 → Feb 2020	menstrual disorder, venous thromboembolism	Indiana University	Completed	No outcome recorded
Phase 329 trials
Phase 3	NCT07626411 Comparator	Jul 2026 → Sep 2029 expected	atrial fibrillation	Regeneron Pharmaceuticals	Not yet recruiting	No outcome recorded
Phase 3	NCT07493304 Comparator	Jun 2026 → Jul 2031 expected	venous thromboembolism	Regeneron Pharmaceuticals	Recruiting	No outcome recorded
Phase 3	NCT07434661 Comparator	Feb 2026 → Jan 2028 expected	aortic valve disorder, atrial fibrillation, cardiac valvular defect	Meshalkin Research Institute of Pathology of Circulation	Not yet recruiting	No outcome recorded
Phase 3	NCT07228663 Comparator	Dec 2025 → Jul 2027 expected	venous thromboembolism	McMaster University	Not yet recruiting	No outcome recorded
Phase 3	NCT07015905 Comparator	Jun 2025 → Feb 2027 expected	venous thromboembolism	Regeneron Pharmaceuticals	Recruiting	No outcome recorded
Phase 3	NCT06322953 Comparator	Mar 2025 → Dec 2027 expected	traumatic brain injury	Walton Centre NHS Foundation Trust	Recruiting	No outcome recorded
Phase 3	NCT06370273 Comparator	Nov 2024 → Aug 2028 expected	thrombotic disease	Queen Mary University of London	Recruiting	No outcome recorded
Phase 3	NCT05894954 Background	Jul 2023 → Oct 2025	cognitive impairment with or without cerebellar ataxia, dementia	Alzheimer's Prevention and Reversal Project, Inc.	Completed	No outcome recorded
Phase 3	NCT05757869 Comparator	Apr 2023 → Oct 2026 expected	atrial fibrillation	Janssen Research & Development, LLC	Active not recruiting	No outcome recorded
Phase 3	NCT05679024 Comparator	Feb 2023 → Dec 2027 expected	atrial fibrillation, chronic kidney disease, intracerebral hemorrhage, venous thromboembolism	Region Stockholm	Recruiting	No outcome recorded
Phase 3	NCT05643573 Comparator	Dec 2022 → Jan 2024	atrial fibrillation	Bayer	Terminated	No outcome recorded
Phase 3	NCT05171049 Comparator	May 2022 → Feb 2026	pulmonary embolism, venous thromboembolism	Anthos Therapeutics, Inc.	Terminated	No outcome recorded
Phase 3	NCT06531122 Comparator	Aug 2021 → Sep 2024 overdue	cerebral sinovenous thrombosis	Kafrelsheikh University	Recruiting	No outcome recorded
Phase 3	NCT06551415 Comparator	Aug 2021 → Sep 2024 overdue	cerebral sinovenous thrombosis	Kafrelsheikh University	Recruiting	No outcome recorded
Phase 3	NCT04284839 Comparator	Jul 2021 → Jun 2027 expected	—	Population Health Research Institute	Recruiting	No outcome recorded
Phase 3	NCT04891861 Comparator	Jul 2021 → Jul 2023	hyperheparinemia	University of Texas at Austin	Unknown	No outcome recorded
Phase 3	NCT04801940 Comparator	May 2021 → Jan 2024	COVID-19	Cambridge University Hospitals NHS Foundation Trust	Unknown	No outcome recorded
Phase 3	NCT04650087 Comparator	Feb 2021 → Jul 2022	COVID-19	Thomas L. Ortel	Completed	No outcome recorded
Phase 3	NCT04498273 Comparator	Sep 2020 → Aug 2021	COVID-19	Frank C Sciurba	Terminated	No outcome recorded
Phase 3	NCT03907046 Comparator	Jan 2020 → Apr 2027 expected	atrial fibrillation, intracerebral hemorrhage	Yale University	Recruiting	No outcome recorded
Phase 3	NCT04462003 Comparator	Jul 2019 → Jul 2020	cancer, venous thromboembolism	Beni-Suef University	Unknown	No outcome recorded
Phase 3	NCT04007289 Comparator	Jun 2019 → Jul 2026 overdue	portal hypertension, noncirrhotic	Assistance Publique - Hôpitaux de Paris	Active not recruiting	No outcome recorded
Phase 3	NCT03839355 Comparator	Dec 2018 → Dec 2020	atrial fibrillation	Mayo Clinic	Terminated	No outcome recorded
Phase 3	NCT03692065 Comparator	Oct 2018 → Sep 2024	blood coagulation disease	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT03232398 Comparator	Jan 2018 → Mar 2021	acute myocardial infarction, thrombotic disease	Hadassah Medical Organization	Completed	No outcome recorded
Phase 3	NCT02933697 Comparator	Jun 2017 → Jul 2022	atrial fibrillation, end stage renal failure	Atrial Fibrillation Network	Completed	No outcome recorded
Phase 3	NCT02179177 Comparator	Jan 2015 → Sep 2017	sickle cell disease	Nirmish Shah	Terminated	No outcome recorded
Phase 3	NCT01924065 Comparator	Aug 2013 → Aug 2017	atrial fibrillation, stroke disorder	Suleyman Demirel University	Completed	No outcome recorded
Phase 3	NCT00831441 Comparator	Mar 2009 → Mar 2011	acute coronary syndrome	Bristol-Myers Squibb	Terminated	No outcome recorded

Phase 427 trials
Phase 4	NCT06953726 Comparator	Jun 2026 → Oct 2032 expected	atrial fibrillation	VA Office of Research and Development	Recruiting	No outcome recorded
Phase 4	NCT06650501 Comparator	Jan 2026 → Jan 2030 expected	infective endocarditis, staphylococcal toxemia, staphylococcus aureus infection	McGill University Health Centre/Research Institute of the McGill University Health Centre	Recruiting	No outcome recorded
Phase 4	NCT06212674 Comparator	Oct 2025 → Oct 2027 expected	atrial fibrillation, ischemic stroke	Medical University of Silesia	Recruiting	No outcome recorded
Phase 4	NCT06862726 Comparator	Dec 2024 → Dec 2025 overdue	atrial fibrillation	Les Laboratoires des Médicaments Stériles	Enrolling by invitation	No outcome recorded
Phase 4	NCT03129555 Comparator	Apr 2023 → Mar 2027 expected	pulmonary embolism, venous thromboembolism	Herlev and Gentofte Hospital	Active not recruiting	No outcome recorded
Phase 4	NCT03129490 Comparator	Apr 2023 → Oct 2027 expected	atrial fibrillation, atrial flutter	Herlev and Gentofte Hospital	Active not recruiting	No outcome recorded
Phase 4	NCT04642430 Comparator	Jul 2021 → Dec 2027 expected	atrial fibrillation	Ottawa Hospital Research Institute	Recruiting	No outcome recorded
Phase 4	NCT04746339 Comparator	Mar 2021 → May 2022	COVID-19, thrombotic disease	Brazilian Clinical Research Institute	Terminated	No outcome recorded
Phase 4	NCT04666454 Comparator	Dec 2020 → Dec 2028 expected	Tako-tsubo cardiomyopathy	Vastra Gotaland Region	Recruiting	No outcome recorded
Phase 4	NCT04250116 Background	Apr 2020 → Apr 2025 overdue	atrial fibrillation	Yonsei University	Active not recruiting	No outcome recorded
Phase 4	NCT03988842 Background	Jul 2019 → Apr 2020	acute cor pulmonale, pulmonary embolism, pulmonary embolism and infarction	Victor Tapson, MD	Terminated	No outcome recorded
Phase 4	NCT03590743 Comparator	Feb → Jun 2019	venous thromboembolism	Mayo Clinic	Terminated	No outcome recorded
Phase 4	NCT03568890 Comparator	Sep 2018 → Aug 2025 overdue	hemorrhagic disease, thrombotic disease, transient ischemic attack	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	Active not recruiting	No outcome recorded
Phase 4	NCT03196349 Comparator	Aug 2018 → May 2019	venous thromboembolism	Duke University	Terminated	No outcome recorded
Phase 4	NCT03463317 Comparator	Feb 2018 → Nov 2024	atrial fibrillation	Charite University, Berlin, Germany	Completed	No outcome recorded
Phase 4	NCT03266783 Comparator	Dec 2017 → Apr 2025	venous thromboembolism	Ottawa Hospital Research Institute	Completed	No outcome recorded
Phase 4	NCT02406885 Comparator	Jul 2017 → Feb 2020	obesity disorder	Johns Hopkins University	Completed	No outcome recorded
Phase 4	NCT02735902 Background	Jun 2017 → Feb 2023	—	Nîmes University Hospital	Completed	No outcome recorded
Phase 4	NCT03062319 Comparator	Apr 2017 → Jul 2023	atherosclerosis, atrial fibrillation, ischemic stroke	National Hospital Organization Osaka National Hospital	Terminated	No outcome recorded
Phase 4	NCT02559856 Comparator	May 2016 → Nov 2017	venous thromboembolism	Ottawa Hospital Research Institute	Completed	No outcome recorded
Phase 4	NCT02701062 Background	Feb 2016 → Apr 2019	atrial fibrillation	AtriCure, Inc.	Completed	No outcome recorded
Phase 4	NCT02666157 Comparator	Jan 2016 → Dec 2018	atrial fibrillation	National Cheng-Kung University Hospital	Unknown	No outcome recorded
Phase 4	NCT02608099 Comparator	Nov 2015 → Apr 2017	atrial fibrillation	Baim Institute for Clinical Research	Completed	No outcome recorded
Phase 4	NCT02935855 Comparator	Sep 2015 → Apr 2019	diabetes mellitus	University of Pavia	Completed	No outcome recorded
Phase 4	NCT02415400 Comparator	Jun 2015 → Nov 2018	acute coronary syndrome	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 4	NCT02090075 Comparator	Sep 2014 → Dec 2016	atrial fibrillation	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Completed	No outcome recorded
Phase 4	NCT01962545 Background	Nov 2013 → May 2017	atrial fibrillation, coronary artery disorder	Satoshi Shizuta	Completed	No outcome recorded

Phase not applicable14 trials
—	NCT07497893 Background	Dec 2026 → Nov 2029 expected	atrial fibrillation	Ewha Womans University Mokdong Hospital	Not yet recruiting	No outcome recorded
—	NCT07583784 Comparator	Jul 2026 → Dec 2031 expected	ST-elevation myocardial infarction, atrial fibrillation	Chonnam National University Hospital	Not yet recruiting	No outcome recorded
—	NCT06866665 Comparator	Mar 2025 → Dec 2030 expected	atrial fibrillation, coronary artery disorder	Yonsei University	Not yet recruiting	No outcome recorded
—	NCT06699342 Comparator	Jan 2025 → Dec 2027 expected	atrial fibrillation	Seoul National University Hospital	Recruiting	No outcome recorded
—	NCT06055920 Comparator	Nov 2023 → Jul 2026 overdue	pulmonary embolism	Inari Medical	Active not recruiting	No outcome recorded
—	NCT05705076 Comparator	Jan 2023 → Mar 2024	hyperheparinemia	Mansoura University	Unknown	No outcome recorded
—	NCT05701917 Comparator	Jan 2023 → Jun 2026 overdue	post-thrombotic syndrome, venous thromboembolism	Inari Medical	Recruiting	No outcome recorded
—	NCT05472766 Comparator	Nov 2022 → Mar 2024	atrial fibrillation	Sunnybrook Health Sciences Centre	Terminated	No outcome recorded
—	NCT05622500 Background	Sep 2022 → Apr 2025	chronic venous insufficiency, post-thrombotic syndrome	Imperial College London	Terminated	No outcome recorded
—	NCT06449469 Background	May 2021 → Apr 2026 overdue	aortic valve stenosis	Rigshospitalet, Denmark	Active not recruiting	No outcome recorded
—	NCT03465735 Background	Jan 2017 → Aug 2019	venous thromboembolism	Mayo Clinic	Terminated	No outcome recorded
—	NCT02744092 Comparator	Dec 2016 → Oct 2020	cancer, pulmonary embolism, thrombotic disease, venous thromboembolism	Alliance Foundation Trials, LLC.	Completed	No outcome recorded
—	NCT02633774 Comparator	Nov 2015 → Nov 2020	persistent atrial fibrillation	Yonsei University	Unknown	No outcome recorded
—	NCT01999179 Background	Jun 2014 → Apr 2019	neoplasm, venous thromboembolism	Medical College of Wisconsin	Completed	No outcome recorded

Phase not stated1 trial
—	NCT05187286 Background	—	—	Bristol-Myers Squibb	Available	No outcome recorded

Press releases naming this drug 14 releases

Date	Issuer	Release
2019-12-07	Pfizer	Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer pfizer.com ↗
2019-03-17	Pfizer	AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention pfizer.com ↗
2019-03-17	Bristol-Myers Squibb	AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention bms.com ↗
2017-08-28	Pfizer	Bristol-Myers Squibb and Pfizer Present Investigational Eliquis® (apixaban) Data for Patients with Non-Valvular Atrial Fibrillation (NVAF) Undergoing Cardioversion pfizer.com ↗
2017-08-27	Pfizer	Bristol-Myers Squibb and Pfizer Present Observational Real-World Data Analysis on the Effectiveness and Safety of Eliquis® (apixaban) Compared to Warfarin in Select High-Risk Patients with Non-Valvular Atrial Fibrillation pfizer.com ↗
2017-03-06	Pfizer	Bristol-Myers Squibb and Pfizer to Present New Analyses of Eliquis™ (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session pfizer.com ↗
2016-11-10	Pfizer	Bristol-Myers Squibb and Pfizer to Deliver 12 New Eliquis® (apixaban) Presentations at American Heart Association (AHA) Scientific Sessions 2016 pfizer.com ↗
2016-08-23	Pfizer	Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016 pfizer.com ↗
2016-03-30	Pfizer	Bristol-Myers Squibb and Pfizer Announce Global Real-World Data Program and Present New Analyses of Eliquis (apixaban) at the American College of Cardiology’s 65th Annual Scientific Session pfizer.com ↗
2015-12-10	Pfizer	AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism (VTE), VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy pfizer.com ↗
2015-12-10	Bristol-Myers Squibb	AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism (VTE), VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy bms.com ↗
2015-11-06	Pfizer	Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the American Heart Association (AHA) Scientific Sessions 2015 pfizer.com ↗
2015-09-09	Pfizer	Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention pfizer.com ↗
2015-08-24	Pfizer	Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015 pfizer.com ↗

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 264 sources stand behind the page.

Field	Value	Cited text
Known as	Apixaban	“Pharmacologic therapy includes rate control with beta-blockers (e.g., bisoprolol), calcium channel blockers (e.g., diltiazem), or antiarrhythmic drugs (e.g., flecainide,...” NCT06699342 ↗ 260 “Patients will be chronically treated with NOAC including apixaban (2x5 mg or 2x2.5 mg depending on the dose reduction regimen) or dabigatran (2x150 mg or 2x110 mg depending on...” NCT06212674 ↗ “DOACs (eg Apixaban, dabigatran, edoxaban and rivaroxaban) are recommended by The National Institute for Health and Care Excellence (NICE) for those over 65 with AF and a...” NCT06322953 ↗ “For those randomized to group B (NOAC group), patients will be treated using a registered NOAC (rivaroxaban, apixaban or dabigatran, but preferentionally apixaban) at the dose...” NCT02426944 ↗ “NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice...” NCT01962545 ↗ “edoxaban 60 mg daily (dose reduction to 30 mg, if applicable), apixaban 5 mg twice daily (dose reduction to 2.5 mg, if applicable), dabigatran 110 mg twice daily, or...” NCT03968393 ↗ “Non-vitamin K antagonist oral anticoagulant therapy (e.g., apixaban, rivaroxaban, dabigatran, or edoxaban) administered according to approved labeling and guideline-recommended dosing.” NCT07497893 ↗ “Participants in the continuation arm will receive oral anticoagulant drugs such as dabigatran, rivaroxaban, apixaban, warfarin, etc. tailored to their specific risk profiles.” NCT06615596 ↗ “Patients allocated to the DAT group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 15 mg once daily with clopidogrel 75 mg once daily.” NCT07583784 ↗ “Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) or rivaroxaban 20mg once daily (15mg once daily if meets dose-reduction criteria) for 2 years” NCT04437654 ↗ “Antithrombotic agents include, but are not limited to: warfarin (titrated to international normalised ratio, INR), apixaban, rivaroxaban, aspirin, and clopidogrel.” NCT05622500 ↗ “Patients enrolled in the NOAC monotherapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 20 mg once daily for 2 years after randomization.” NCT04250116 ↗ “Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.” NCT06055920 ↗ “The patient will receive apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily during a mean follow-up period of 36 months (12 to 65 months)” NCT03285438 ↗ “Patients who are over 20 years old, have non-valvular atrial fibrillation, and are taking rivaroxaban, apixaban, or edoxaban (active ingredients)” NCT05801068 ↗ “Patients randomized to receive DOAC, at the choice of the investigator: Apixaban 2.5 mg both in day or Rivaroxaban 10 mg once daily.” NCT05198960 ↗ “DOA study medications (Apixaban, Rivaroxaban and Dabigatran) will be prescribed and supplied in the usual setting of patient care” NCT05825573 ↗ “Administration of approved DOACs (e.g., apixaban, rivaroxaban, edoxaban, or dabigatran) at standard stroke prevention dosages.” NCT07609654 ↗ “Oral factor Xa inhibitors (oral FXaI, eg, apixaban, edoxaban or rivaroxaban) are commonly prescribed for this indication.” PMID 41387009 ↗ Dec 2025 “Participants will receive apixaban orally twice a day through the time of venography (or day 12, whichever is earlier)” NCT05618808 ↗ “Apixaban or dabigatran or edoxaban or rivaroxaban at recommended dosing for stroke prevention in atrial fibrillation.” NCT02998905 ↗ “Participants in the anticoagulation monotherapy group will receive apixaban 5 mg twice daily during the study period.” NCT06866665 ↗ “Patients will be treated with one of the available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban.” NCT03642509 ↗ “novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.” NCT02504177 ↗ “Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)” NCT05387954 ↗ “The Direct oral anticoagulant treatment : Apixaban 5 mg x2 or 2.5 mg X2, Edoxaban 30 ou 60 mg” NCT02735902 ↗ “choice of DOAC (apixaban, dabigatran, edoxaban or rivaroxaban) according to local practice” NCT04700826 ↗ “Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP” NCT05472766 ↗ “any approved direct oral anticoagulant (apixaban, rivaroxaban, edoxaban or dabigatran)” NCT04045665 ↗ “direct oral anticoagulant treatment (apixaban, rivaroxaban, dabigatran, or edoxaban)” NCT01999179 ↗ “Anticoagulation agents includes rivaroxaban, dabigatran, apixaban, and edoxaban.” NCT06057467 ↗ “Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban” NCT06401616 ↗ “Anticoagulation with a NOAC (Apixaban, Dabigatran, Edoxaban, Rivaroxaban)” NCT05006287 ↗ “warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage” NCT01924065 ↗ “New oral anticoagulants (NOACs): dabigatran, rivaroxaban, apixaban” NCT02701062 ↗ “warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban” NCT03062319 ↗ “Multiple-dose clarithromycin and single-dose Apixaban” NCT02912234 ↗ “Apixaban (Eliquis) at 2.5mg, per os, twice a day” NCT06045858 ↗ “prophylactic oral anticoagulation with apixaban” NCT05089227 ↗ “Apixaban: 5 mg twice daily or 2.5 twice daily” NCT06862726 ↗ “dabigatran, apixaban, edoxaban, rivaroxaban” NCT03759938 ↗ “Rivaroxaban 10 mg OD or apixaban 2.5 mg BID” NCT07228663 ↗ “Therapies group A : Apixaban 2.5 mg twice” NCT05705076 ↗ “Apixaban Dabigatran Edoxaban Rivaroxaban” NCT05292846 ↗ “Apixaban (Eliquis)” NCT07011095 ↗ “Apixaban (Eliquis)” NCT03465735 ↗ “Apixaban (Eliquis)” NCT01706146 ↗ NCT03266783 ↗ NCT02080858 ↗ NCT02749617 ↗ NCT03129490 ↗ NCT06689436 ↗ NCT05208398 ↗ NCT07312851 ↗ NCT04865978 ↗ NCT04746339 ↗ NCT02565693 ↗ NCT04218266 ↗ NCT02262520 ↗ NCT05995119 ↗ NCT07493304 ↗ NCT06515730 ↗ NCT02935855 ↗ NCT06486792 ↗ NCT07175428 ↗ NCT02450682 ↗ NCT05735639 ↗ NCT07709780 ↗ NCT04650087 ↗ NCT04512079 ↗ NCT03136510 ↗ NCT05687448 ↗ NCT02100228 ↗ NCT03509883 ↗ NCT07404345 ↗ NCT07189897 ↗ NCT04243122 ↗ NCT05484557 ↗ NCT03988842 ↗ NCT02366871 ↗ NCT07626411 ↗ NCT04788355 ↗ NCT00633893 ↗ NCT01707394 ↗ NCT04278729 ↗ NCT03083782 ↗ NCT01675076 ↗ NCT03961334 ↗ NCT07237308 ↗ NCT03083704 ↗ NCT03692065 ↗ NCT02664155 ↗ NCT07015905 ↗ NCT04498273 ↗ NCT04981327 ↗ NCT07461545 ↗ NCT04168203 ↗ NCT07461532 ↗ NCT03080883 ↗ NCT02066454 ↗ NCT06742567 ↗ NCT00496769 ↗ NCT02048865 ↗ NCT02581176 ↗ NCT07270263 ↗ NCT05869591 ↗ NCT00371683 ↗ NCT02946944 ↗ NCT07521332 ↗ NCT00831441 ↗ NCT05171049 ↗ NCT04809818 ↗ NCT03398434 ↗ NCT03463317 ↗ NCT07160686 ↗ NCT04432220 ↗ NCT03148457 ↗ NCT02599532 ↗ NCT05723510 ↗ NCT05419583 ↗ NCT02179177 ↗ NCT07246005 ↗ NCT05491460 ↗ NCT04284839 ↗ NCT02744092 ↗ NCT04645550 ↗ NCT02633774 ↗ NCT02672709 ↗ NCT06953726 ↗ NCT03935451 ↗ NCT07005024 ↗ NCT00643201 ↗ NCT01884350 ↗ NCT05679024 ↗ NCT03678506 ↗ NCT02942407 ↗ NCT04891861 ↗ NCT04801940 ↗ NCT03907046 ↗ NCT01884337 ↗ NCT02074358 ↗ NCT04344717 ↗ NCT03590743 ↗ NCT03594045 ↗ NCT02585713 ↗ NCT00313300 ↗ NCT04229264 ↗ NCT05757869 ↗ NCT03232398 ↗ NCT03045406 ↗ NCT02283294 ↗ NCT05304455 ↗ NCT02415400 ↗ NCT06449469 ↗ NCT05643573 ↗ NCT00423319 ↗ NCT04128254 ↗ NCT04006093 ↗ NCT03243175 ↗ NCT00852397 ↗ NCT02369653 ↗ NCT00562289 ↗ NCT03129555 ↗ NCT01340586 ↗ NCT00320255 ↗ NCT05187286 ↗ NCT04952792 ↗ NCT06531122 ↗ NCT02270918 ↗ NCT06603870 ↗ NCT03139487 ↗ NCT04874428 ↗ NCT00412984 ↗ NCT00452530 ↗ NCT04642430 ↗ NCT05683808 ↗ NCT04504318 ↗ NCT03276143 ↗ NCT01780987 ↗ NCT06864052 ↗ NCT07265466 ↗ NCT04142658 ↗ NCT02464969 ↗ NCT02666157 ↗ NCT05035277 ↗ NCT02982590 ↗ NCT05701917 ↗ NCT04462003 ↗ NCT02101112 ↗ NCT00914641 ↗ NCT04479579 ↗ NCT04191928 ↗ NCT06370273 ↗ NCT05088928 ↗ NCT02034591 ↗ NCT02406885 ↗ NCT02034578 ↗ NCT02034565 ↗ NCT02981472 ↗ NCT06729034 ↗ NCT03310021 ↗ NCT07559942 ↗ NCT03196349 ↗ NCT06372483 ↗ NCT02958969 ↗ NCT01195727 ↗ NCT01758432 ↗ NCT02829957 ↗ NCT06474182 ↗ NCT04106700 ↗ NCT04007289 ↗ NCT04489849 ↗ NCT02945280 ↗ NCT04666454 ↗ NCT04041843 ↗ NCT00252005 ↗ NCT03153150 ↗ NCT03456648 ↗ NCT02262533 ↗ NCT02809469 ↗ NCT02933697 ↗ NCT03568890 ↗ NCT03200613 ↗ NCT05632445 ↗ NCT00787150 ↗ NCT07434661 ↗ NCT04850378 ↗ NCT04023760 ↗ NCT07471139 ↗ NCT00457002 ↗ NCT07699796 ↗ NCT02889562 ↗ NCT04974684 ↗ NCT01938248 ↗ NCT02664649 ↗ NCT07713875 ↗ NCT02608099 ↗ NCT02227550 ↗ NCT02295475 ↗ NCT06523959 ↗ NCT03839355 ↗ NCT03192215 ↗ NCT01437839 ↗ NCT04002011 ↗ NCT06551415 ↗ NCT03181386 ↗ NCT01924325 ↗ NCT02559856 ↗ NCT03987711 ↗ NCT03251482 ↗ NCT05152420 ↗ NCT02427126 ↗ NCT00097357 ↗ NCT02378623 ↗ NCT03996772 ↗ NCT02090075 ↗ NCT07132515 ↗ NCT05973188 ↗ NCT06886516 ↗ NCT04696120 ↗ NCT03288454 ↗
Known as	Apixaban (Eliquis)	“Apixaban (Eliquis)” NCT07011095 ↗ 2 “Apixaban (Eliquis)” NCT01706146 ↗ “Apixaban (Eliquis)” NCT03465735 ↗
Known as	Apixaban IR	“Drug: Apixaban IR” NCT00914641 ↗
Known as	Apixaban MR1	“Drug: Apixaban MR1” NCT00914641 ↗
Known as	Apixaban MR2	“Drug: Apixaban MR2” NCT00914641 ↗
Known as	Apixaban MR3	“Drug: Apixaban MR3” NCT00914641 ↗
Known as	Apixiban	“The name of the study drug involved in this study is: -Apixiban (a type of anticoagulant)” NCT06886516 ↗
Known as	Eliquis	“This study will test different ways of using a commonly prescribed blood thinner called apixaban (brand name Eliquis) to see if it can safely and effectively reduce the risk of...” NCT07005024 ↗ 9 “Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)” NCT03148457 ↗ “novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.” NCT02504177 ↗ “The two most commonly-used anticoagulants will be compared: apixaban (Eliquis) and rivaroxaban (Xarelto).” NCT06953726 ↗ “Vascular treatments may include: antihypertensives, Ubrelvy, aspirin, Eliquis” NCT05894954 ↗ “Apixaban (Eliquis) at 2.5mg, per os, twice a day” NCT06045858 ↗ “Apixaban 2.5 MG Oral Tablet [ELIQUIS]” NCT04981327 ↗ “Apixaban 5 MG [Eliquis]” NCT05869591 ↗ “Apixaban (Eliquis)” NCT06729034 ↗ NCT06933056 ↗
Known as	Eliquis 2,5mg	“Apixaban 2.5mg (i.e Eliquis® 2,5mg tablet) orally twice daily for 28 days (with standard of care mechanical prophylaxis)” NCT06523959 ↗
Known as	TAH3311	“A Pivotal, Randomized, Single-dose, Open-label, Four-Way Crossover, BE Study of TAH3311 (Apixaban ODF) Under Fasted and Fed Conditions vs. ELIQUIS® Oral Tablet Under Fasted...” NCT06689436 ↗
Action	Inhibit	“oral Factor Xa inhibitor BMS-562247” NCT00097357 ↗
Modality	Small molecule	“Apixaban is an oral small-molecule, direct factor Xa (FXa) inhibitor approved in adults for treatment of deep vein thrombosis and pulmonary embolism, and for reducing risk of...” PMID 36861188 ↗ Mar 2023
Route	Oral	“Tablets, Oral, 12 +/- 2 days” NCT00097357 ↗